Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D2.151 - HZ-Y030, an Oral STAT6 Degrader, Attenuates Type 2 Inflammation in Preclinical Asthma Models
D2.152 - Clinical and functional characteristics of patients with suspected epoxy resin-related occupational asthma
D2.155 - Mapping the Architecture and Spectrum of the Cough Hypersensitivity Questionnaire Across Respiratory Diseases
D2.158 - Circulating 1-methylnicotinamide can predict the treatment response of dupilumab in adult asthma
D2.157 - Clinical remission with tezepelumab in severe asthma: prevalence and predictors in a real-world multicentre study
D2.159 - Idiopathic Chronic Eosinophilic Pneumonia: A Case Series
D2.160 - Household Overcrowding and Number of Siblings as Risk Factors for Uncontrolled Asthma in Inner-City Children
D2.161 - Exploring the Early-Life Interplay Between Respiratory Health and Neurodevelopmental disorders
D3.35 - The influence of birth month on allergen sensitization patterns: A comprehensive analysis of skin prick test results in a large patient cohort
D3.36 - Chronic type non-IgE-mediated gastrointestinal food allergies, Clinical features and unclassified subgroup in the recent cohort
D3.38 - Elucidating the Causes of Discordant Results Between Two Specific IgE Assays Using Component-Resolved Diagnostics and Depletion Testing
D3.39 - Allergic contact dermatitis to oxidized fragrance components: a case of sensitization to hydroperoxides of limonene
D3.44 - Global Trends in Google Search Interest for Allergic Diseases, Diagnostics and Therapies Over Two Decades
D3.46 - Safety of the EAACI risk assessment in hypersensitivity reactions to chemotherapy
D3.47 - Changes in Poaceae and Betulaceae pollen seasons correlate with patient sensitization profiles: a single-centre study over 4 decades
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download